Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(2.85)
# 978
Out of 5,182 analysts
90
Total ratings
35.71%
Success rate
10.67%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INMB INmune Bio | Upgrades: Buy | $2 → $9 | $1.18 | +662.71% | 1 | Mar 11, 2026 | |
| XOMA XOMA Royalty | Initiates: Buy | $76 | $36.79 | +106.58% | 1 | Dec 9, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.06 | +6,126.42% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $240 | $1.35 | +17,677.78% | 1 | Dec 12, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $0.14 | +7,970.43% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $56.08 | -10.84% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.00 | +1,605.97% | 1 | Sep 30, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.90 | +1,447.65% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $1.59 | +4,113.84% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $43 | $22.78 | +88.76% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.17 | +331.65% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $0.52 | +1,354.33% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $3.64 | +312.09% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $5.53 | +587.16% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.70 | +5,614.29% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $6.63 | +654.15% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $6.11 | +3,173.32% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $15.72 | +109.92% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $40.79 | -1.94% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $0.24 | +15,278.22% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $5.99 | +434.22% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $8.36 | +821.05% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.80 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $65.14 | -23.24% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $1.78 | +1,753.93% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $11.49 | +126.28% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $259.00 | -89.19% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $4.91 | +17,211.61% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $8.79 | +138.91% | 2 | Jul 12, 2017 |
INmune Bio
Mar 11, 2026
Upgrades: Buy
Price Target: $2 → $9
Current: $1.18
Upside: +662.71%
XOMA Royalty
Dec 9, 2025
Initiates: Buy
Price Target: $76
Current: $36.79
Upside: +106.58%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.06
Upside: +6,126.42%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $240
Current: $1.35
Upside: +17,677.78%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $0.14
Upside: +7,970.43%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $56.08
Upside: -10.84%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.00
Upside: +1,605.97%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.90
Upside: +1,447.65%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $1.59
Upside: +4,113.84%
Alto Neuroscience
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $22.78
Upside: +88.76%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $4.17
Upside: +331.65%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.52
Upside: +1,354.33%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $3.64
Upside: +312.09%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $5.53
Upside: +587.16%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.70
Upside: +5,614.29%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $6.63
Upside: +654.15%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $6.11
Upside: +3,173.32%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $15.72
Upside: +109.92%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $40.79
Upside: -1.94%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $0.24
Upside: +15,278.22%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $5.99
Upside: +434.22%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $8.36
Upside: +821.05%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $9.80
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $65.14
Upside: -23.24%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $1.78
Upside: +1,753.93%
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $11.49
Upside: +126.28%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $259.00
Upside: -89.19%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $4.91
Upside: +17,211.61%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $8.79
Upside: +138.91%